Inclusion Criteria:

- Histologically verified colorectal adenocarcinomas

- Age > 18 years and < 70

- Metastatic colorectal cancer refractory 5-FU, oxaliplatin and irinotecan containing
treatment regimes

- KRAS mutation detected by DxS kit in primary tumor or metastatic lesion.

- Measurable disease according to RECIST

- ECOG performance status 0, 1 or 2

- Adequate renal, hepatic and haematological function

- Normal serum cholesterol and triglycerides

- Blood samples and available paraffin embedded tumor material for translational
research studies

- Fertile males and females (< 2 years after last period for women) must use effective
birth control

- Signed Informed consent

Exclusion Criteria:

- Clinically significant heart disease, active severe infections or other concurrent
disease

- Other malignant diseases within 5 years of inclusion in the study, except basal cell
squamous cell carcinoma of the skin and cervical carcinoma-in-situ

- Prior radiotherapy within 30 days of treatment start

- Other experimental therapy within 30 days of treatment initiation

- Patients who are breast feeding, childbearing or of childbearing potential without
using dual effective contraception

- Clinical or radiological evidence of CNS metastasis

- Completed any major surgery, excision biopsy or significant traumatic lesion ≥ 4
weeks from start of treatment and completed any minor surgery ≥ 1 week prior to start
of treatment

- Insertion of a vascular access device is not considered major or minor surgery
from the viewpoint of protocol eligibility

- Patients must have fully recovered from the procedure and have a fully healed
incision

- Planned radiation therapy against target-lesions

- Patients with significant non-healing wounds or ulcers

- History or evidence of thrombotic or hemorrhagic disorders

- Significant haemorrhage (> 30 ml/bleeding episode in previous 3 months)

- Haemoptysis (> 5 ml fresh blood in previous 4 weeks)

- Patients on full-dose anticoagulation (e.g., warfarin) are eligible provided that
both of the following criteria are met:

- The patient has an in-range INR (usually between 2 and 3) on a stable dose of
oral anticoagulant or is on a stable dose of low molecular weight heparin

- The patient has no active bleeding or pathological condition that carries a high
risk of bleeding (e.g., tumor involving major vessels or known varices)

- Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or
Sub-Arachnoid Hemorrhage (SAH) within 12 months prior to randomization

- No known or history of HIV seropositivity

- The use of ACE inhibitors is not permitted during the study

- Known allergy to temsirolimus, sirolimus, polysorbate 80 or included agents.

- Agents with strong CYP3A4-inhibitory potential